Altoida’s Vision For Alzheimer’s Care Combines Digital Screening, Blood-Best Tests, New Drugs
Executive Summary
Altoida CEO Mark Jones spoke with Medtech Insight about the company’s investigational digital screening tool for Alzheimer’s and the dire need for better, more accessible precision neurology diagnostics as the global population ages, neurologist shortages worsen, and groundbreaking Alzheimer’s drugs that change the treatment paradigm.